Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enamel matrix proteins (EMPs) are a complex mixture of proteins secreted by ameloblasts during the early stages of tooth development. While amelogenin constitutes the majority (approximately 90%) of this matrix, the term "Other enamel matrix proteins" refers to the remaining non-amelogenin components, including ameloblastin, enamelin, tuftelin, and amelotin. These proteins play a critical role in the biomineralization of enamel and the formation of the periodontal attachment apparatus, including cementum and the periodontal ligament. In a therapeutic context, these proteins are typically administered as a porcine-derived Enamel Matrix Derivative (EMD) to promote periodontal regeneration in patients with advanced gum disease. By mimicking the natural odontogenic environment, they stimulate cell signaling pathways that lead to the recruitment and differentiation of progenitor cells necessary for restoring lost periodontal tissues.
Mimicry of the biological environment during tooth development to stimulate the formation of cementum, periodontal ligament, and alveolar bone by promoting the recruitment and differentiation of mesenchymal stem cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enamel matrix proteins (EMPs).